GHRH抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06323(GHRH Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Growth hormone-releasing hormone (GHRH) antibodies are specialized immunological tools designed to target and bind GHRH, a hypothalamic peptide critical for regulating growth hormone (GH) secretion. GHRH stimulates the anterior pituitary gland to produce and release GH, which plays a central role in growth, metabolism, and tissue repair. Dysregulation of the GHRH-GH axis is implicated in disorders like acromegaly, GH deficiency, and certain cancers.

GHRH antibodies are primarily used in research and diagnostics to study GHRH expression, signaling pathways, and its involvement in disease mechanisms. They enable quantification of GHRH levels in biological samples (e.g., serum, tissue) via techniques like ELISA, Western blotting, or immunohistochemistry. In preclinical studies, neutralizing GHRH antibodies have been explored to suppress GH overproduction or block GHRH-driven tumor growth, offering potential therapeutic insights.

These antibodies are available as polyclonal or monoclonal forms, with specificity validated across species (e.g., human, rodent). Challenges include ensuring minimal cross-reactivity with related peptides (e.g., VIP, PACAP) and optimizing binding affinity. Recent advancements in antibody engineering have improved their utility in both basic research and translational applications, though clinical use remains experimental. Overall, GHRH antibodies remain pivotal in elucidating endocrine physiology and developing targeted interventions for GH-related pathologies.